CN112888690A - 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 - Google Patents

取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 Download PDF

Info

Publication number
CN112888690A
CN112888690A CN201980053055.XA CN201980053055A CN112888690A CN 112888690 A CN112888690 A CN 112888690A CN 201980053055 A CN201980053055 A CN 201980053055A CN 112888690 A CN112888690 A CN 112888690A
Authority
CN
China
Prior art keywords
formula
compound
cancer
crystal
maleate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980053055.XA
Other languages
English (en)
Other versions
CN112888690B (zh
Inventor
高鹏
徐洋平
孟庆义
刘飞
孙中英
张克茹
陈智林
江金凤
陆成晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN112888690A publication Critical patent/CN112888690A/zh
Application granted granted Critical
Publication of CN112888690B publication Critical patent/CN112888690B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本申请属于药物化学领域，涉及取代的吡咯并嘧啶类CDK抑制剂的盐，具体涉及化合物7‑环戊基‑6‑N,N‑二甲氨基甲酰基‑N‑(5‑(1,2,3,6‑4H‑吡啶‑4‑基)吡啶‑2‑基)‑7H‑吡咯并[2,3‑d]嘧啶‑2‑胺马来酸盐(式II化合物)、式II化合物的晶型、其制备方法、药物组合物，还涉及该化合物盐及其药物组合物在制备治疗与CDK4和/或CDK6抑制作用相关的疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980053055.XA 2018-09-13 2019-09-12 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 Active CN112888690B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811068352 2018-09-13
CN2018110683525 2018-09-13
PCT/CN2019/105583 WO2020052627A1 (zh) 2018-09-13 2019-09-12 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途

Publications (2)

Publication Number Publication Date
CN112888690A true CN112888690A (zh) 2021-06-01
CN112888690B CN112888690B (zh) 2022-04-12

Family

ID=69776755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053055.XA Active CN112888690B (zh) 2018-09-13 2019-09-12 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途

Country Status (5)

Country Link
JP (1) JP2022500458A (zh)
CN (1) CN112888690B (zh)
AU (1) AU2019338032A1 (zh)
CA (1) CA3112496A1 (zh)
WO (1) WO2020052627A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023179793A1 (zh) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162215A1 (zh) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186856B (zh) * 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162215A1 (zh) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途

Also Published As

Publication number Publication date
WO2020052627A1 (zh) 2020-03-19
CN112888690B (zh) 2022-04-12
JP2022500458A (ja) 2022-01-04
CA3112496A1 (en) 2020-03-19
AU2019338032A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
US10611762B2 (en) Crystalline forms of a FGFR inhibitor and processes for preparing the same
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
WO2017219948A1 (en) Crystalline forms of triazolopyrimidine compound
US11040979B2 (en) Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
US20180291005A1 (en) Stable crystal form of tipiracil hydrochloride and crystallization method for the same
CN110759908B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
TW200838512A (en) Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
US20230331703A1 (en) Egfr inhibitors
US20210309640A1 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2021238817A1 (zh) 大环jak抑制剂及其应用
EP3812386A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN112888690B (zh) 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
CN111205290B (zh) 一种jak激酶抑制剂的结晶形式及其制备方法
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN109476634B (zh) 喹唑啉衍生物的盐的晶体
US11111234B2 (en) Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
WO2011145548A1 (ja) ジ（アリールアミノ）アリール化合物の結晶
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
US11160806B2 (en) Salt of N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino) piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, its preparation, and formulations containing it
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
KR20230026384A (ko) 화합물의 결정 형태
CN117769560A (zh) Egfr抑制剂的盐、晶型及其组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050133

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant